



Cl  
Conf.



FORMULA I

Wherein:

R represents  $-\text{CO}-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_3$ ,  
 $-\text{CO}-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}(\text{CH}_3)_2$ ,  
 $-\text{CO}-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CH}_3)_2$ ,  
 $-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_3$ ,  
 $-\text{CO}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}(\text{CH}_3)_2$  or



R" represents alpha-D-mannopyranosyl or 2-O-alpha-D-mannopyranosyl-alpha-D-mannopyranosyl, or

R' represents 2,3-0-di[alpha-D-mannopyranosyl]-D-mannopyranosyl and R represents  $\text{-CO-CH=CH-CH=CH-CH}_2\text{-CH (CH}_3)_2$ ,

*C1*  
*Conclusion*  
a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof in any proportion, in admixture with an amount of fat emulsion product for intravenous administration being a lipid in water microemulsion suitable to be administered by the parental route comprising an oil phase, an emulsifier, and at least one additive as an osmotic agent wherein the concentration of the oil phase is from 0.2% to 40% (weight/vol) in the final intravenous formulation and comprises at least one vegetal oil consisting of soybean oil, cottonseed oil and sunflower oil which are partially or totally substituted with a mixture of long chain fatty acids in the form of triglycerides having a percent (wt/wt) composition substantially similar to that of the vegetal oil, and the emulsifier is based on at least one phospholipid.

---

*C2*  
6. (Twice Amended) A formulation according to Claim 1 wherein the oil phase contains long chain fatty acids in the form of triglycerides in the following proportions by weight:

linoleic acid	40-70%
oleic acid	15-30%
palmitic acid	5-15%
linoleic acid	3-12%
stearic acid	2-6%

C2  
conclude

wherein the % is wt% based on the total fatty acid content and the total proportions are selected to add up to 100%.

C3

7. (Thrice Amended) A formulation according to claim 1 wherein the fat emulsion product employed for the preparation of said formulation comprises a composition selected from those reported in the following tables:

	Fat emulsion product 1	Fat emulsion product 2	Fat emulsion product 3
Soybean oil (w/vol)	10%	20%	5%
Safflower oil (w/vol)	--	--	5%
Egg yolk phospholipids (w/vol)	1.2%	1.2%	1.2%
Glycerol (w/vol)	2.25%	2.25%	2.5%
Fatty acids composition of vegetable oils (w/vol)			
Linoleic acid	50%	50%	65.8%
Oleic acid	26%	26%	17.7%
Palmitic acid	10%	10%	8.8%
Linolenic acid	9%	9%	4.2%
Stearic acid	3.5%	3.5%	3.4%
Osmolarity (mOsm/L)	260	268	276
Approximate pH	8	8	8
Fat particle size (μm)	0.5	0.5	0.4
Caloric value (cal/ml)	1.1	2.0	1.1
Size (ml)	50, 100	50, 100	25, 50
	250 or	250 or	100, 200
	500	500	Or 500

C3  
Conclude

	Fat emulsion product 4	Fat emulsion product 5	Fat emulsion product 6
Soybean oil (w/vol)	10%	10%	20%
Safflower oil (w/vol)	10%	--	--
Egg yolk phospholipids (w/vol)	1.2%	1.2%	1.2%
Glycerol (w/vol)	2.5%	2.5%	2.5%
Fatty acids composition of vegetable oil (w/vol)			
Linoleic acid	65.8%	54.5%	54.5%
Oleic acid	17.7%	22.4%	22.4%
Palmitic acid	8.8%	10.5%	10.5%
Linolenic acid	4.2%	8.3%	8.3%
Stearic acid	3.4%	4.2%	4.2%
Osmolarity (mOsm/L)	258	284	292
Approximate pH	8.3	8.3	8.3
Fat particle size (μm)	0.4	0.4	0.4
Caloric value (cal/ml)	2.0	1.1	2.0
Size (ml)	25, 50	100, 200	200 or
	200 or	Or 500	550
	500		

and water for injection is from quantum sufficit to 100% wherein the above are selected so that the total composition adds up to 100%.

C4

14. (Thrice Amended) A formulation according to claim 1 for treatment of infections caused by bacteria whose proliferation is inhibited, reduced, alleviated, or arrested in the presence of ramoplanin or a member of the ramoplanin family.

15. (Thrice Amended) A method of treating at least one Gram positive infection, comprising administering the formulation according to claim 1 to a patient in need thereof.

42. (Twice Amended) The method according to Claim 15, wherein the at least one Gram positive infection is at least one member selected from the group consisting of bacteremia, endocarditis, and pneumonia.--

Please add the following claims.

--43. (New) The formulation according to Claim 1, wherein the phospholipid emulsifier is based on phospholipid from an egg source.

phospho

44. (New) The formulation according to Claim 1, wherein the phospholipid emulsifier is based on a phospholipid selected from egg lecithin, soybean lecithin, or a mixture thereof.

45. (New) The formulation according to Claim 1, wherein the osmotic agent is at least one member selected from the group consisting of sorbitol, glycerol, and xylitol.

46. (New) The formulation according to Claim 1, wherein the oil phase is present in an amount ranging from 4 to 25% wt/vol of the final formulation.

47. (New) The formulation according to Claim 1, wherein the oil phase is present in an amount ranging from 8 to 18% wt/vol of the final formulation.